HIGHLIGHTS
It’s been an interesting start to 2024. The S&P500 came out of the gate down for the first six trading days of the year only to rally into month end to close with a 1.59% gain, excluding dividends. The Wellvest H&W Index stumbled out of the box and never regained its footing resulting in a loss of 7.21 for the month, excluding dividends. A contrarian would believe that the WVC H&W Index is due for an upswing, as the index was down YTD every day in January except the first trading day of the month.
MOVING THE GLP-1 DECK CHAIRS
The potential impact of “GLP-1” drugs (i.e., Ozempic®, Wegovy®) has been widely reported in the mass and financial media. In 2023 this spiked the stock prices of anything and everything that provided exposure, including pharmaceutical companies, teledoc providers and WW International (WW) (better known as Weight Watchers). In early January, Eli Lilly (LLY) announced “LillyDirect”, an online platform that provides streamlined access for consumers to GLP-1 drugs. This undercut the investment thesis that had pushed WW to a 127% gain in 2023, resulting in WW crashing to a 57.0% loss for the month of January. Conversely, LLY continues to march higher into nosebleed territory, ending the month at a 65x EV/EBITDA valuation. If these drugs do become the elusive “silver bullet” that so many are claiming, the implications are far reaching, and will heavily influence healthcare, pharma, food/beverage, supplements, fitness, and even fashion. Heading deeper into 2024 keep an eye on this rapidly evolving situation.
H&W INDEX WINNERS and LOSERS – YTD
- Top Five Winners
|
|
|
|
|
|
|
|
|
|
- Top Five Losers
|
|
|
|
|
|
|
|
|
|
Please visit Wellvest’s library of insights and articles at www.wellvestcapital.com/newsroom
Data sources: Pitchbook. Copyright: Wellvest Capital 2024